Table 3 Multivariate analyses of disease-free survival.

From: Clinical implications of changes in the diversity of c-MYC copy number variation after neoadjuvant chemotherapy in breast cancer

 

Variable

Category

Multivariate analysis

HR

95% CI

P-value

Pre-NAC status

cT stage

T1-2 vs. T3-4

1.057

0.458-2.441

0.896

cN stage

N0 vs. N1-3

10.190

1.367–75.974

0.024

ER status

Positive vs. Negative

1.556

0.508–4.761

0.439

PR status

Positive vs. Negative

2.346

1.043–5.275

0.039

Shannon index for c-MYC CNV

Low vs. High

2.342

1.059–5.182

0.036

Ki-67 index

<20% vs. ≥20%

1.162

0.424–3.187

0.771

Post-NAC status

ypT stage

T1 vs. T2–4

1.515

0.687–3.344

0.303

ypN stage

N0 vs. N1-3

2.638

1.067–6.519

0.036

Miller-Payne grade

Grade 3–4 vs. 1–2

1.019

0.489–2.123

0.960

ER status

Positive vs. Negative

3.400

1.695–6.822

0.001

PR status

Positive vs. Negative

1.905

0.763–4.757

0.167

Shannon index for c-MYC CNV

Low vs. High

2.122

1.071–4.204

0.031

Ki-67 index

<20% vs. ≥20%

1.025

0.348–3.020

0.965

  1. HR, hazard ratio; CI, confidence interval; NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; CNV, copy number variation.
Back to article page